The World Health Organization has authorized the first vaccine to protect against mpox, a crucial step in getting shots to the Democratic Republic of Congo, the center of the outbreak.
The vaccine, Jynneos, was developed by Bavarian Nordic and has already been approved in Europe, the United States, and other high-income countries.
Low- and middle-income countries rely on the W.H.O.'s prequalification process to determine the safety and efficiency of drugs and vaccines.
The W.H.O.'s authorization will make it easier for these countries to access Jynneos and fight the mpox outbreak.
